Published in Vaccine Weekly, January 14th, 2004
Among the new business awards is a consulting and operational support contract with a European pharmaceutical company for a specialized cardiovascular safety study. The emphasis will be on the QT interval effects of a non-cardiac drug as measured on the electrocardiogram in human subjects. The services to be provided for the study will include investigator site selection and management, oversight of subject recruitment, field monitoring, project management and operations, regulatory operations, and medical monitoring.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.